C5a
Synonyms
Prepro-C5, CPAMD4, Complement C5, C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4, C5D, Complement Component 5, C5a, Anaphylatoxin C5a Analog, C5a Anaphylatoxin, C5b, ECLZB, C5,Description
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
KO Status
F0
Drug Information
Launched drugs: 17
Drugs in clinical trials: 2
Latest Research Phase:Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Ravulizumab
ALXN-1210, ALXN-1810
Approved
Alexion Pharmaceuticals Inc
Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Glomerulonephritis, IGA, Coronavirus Disease 2019 (COVID-19), Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Respiratory Distress Syndrome, Adult, Lupus Nephritis, Neuromyelitis Optica, Pneumonia, Viral, Amyotrophic Lateral Sclerosis, Acute Lung Injury
Eculizumab
5G1-1, HAL-1, LEX-98, h-5G1.1
Approved
Alexion Pharmaceuticals
Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome, Delayed Graft Function, Neuromyelitis Optica, Asthma
Zilucoplan
RA-101495, RA-101495-SC
Phase 3 Clinical
Ra Pharma
Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Lupus Nephritis, Hemolytic-Uremic Syndrome
Avacincaptad pegol
ARC-187, ARC-1905
Phase 3 Clinical
Archemix
Geographic Atrophy, Stargardt Disease, Macular Degeneration
Vilobelimab
IFX-1, CaCP-29
Phase 3 Clinical
Beijing Mabworks Biotech Co Ltd, Inflarx
Shock, Septic, Granulomatosis with Polyangiitis, Pyoderma Gangrenosum, Microscopic Polyangiitis, Sepsis, Coronavirus Disease 2019 (COVID-19), Hidradenitis Suppurativa, Systemic Inflammatory Response Syndrome
BDB-001
BDB-001, BDB001, BDB 001
Phase 3 Clinical
Staidson(Beijing) Biopharmaceuticals Co Ltd
Coronavirus Disease 2019 (COVID-19), Neoplasms, Hidradenitis Suppurativa
Eculizumab biosimilar (Biocad)
BCD-148
Phase 3 Clinical
Biocad
Hemoglobinuria, Paroxysmal
Crovalimab
SKY-59, RG-6107, CH-7092230, RO-7092230, RO-7112689, RO-7112689/F01
Phase 3 Clinical
F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd
Hemoglobinuria, Paroxysmal
Eculizumab biosimilar (IBC GENERIUM)
Phase 3 Clinical
Ibc Generium
Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome
Eculizumab biosimilar (Amgen)
ABP-959
Phase 3 Clinical
Amgen Inc
Hemoglobinuria, Paroxysmal, Hemolytic-Uremic Syndrome
Pozelimab
REGN-3918
Phase 3 Clinical
Regeneron Pharmaceuticals Inc
Hemoglobinuria, Paroxysmal
Eculizumab biosimilar (CinnaGen)
Phase 3 Clinical
Cinnagen
Hemoglobinuria, Paroxysmal
Nomacopan
EV-576, rVA576, rEV-576
Phase 3 Clinical
Evolutec
Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Arthritis, Rheumatoid, Sjogren's Syndrome, Autoimmune Diseases, Atypical Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Asthma, Keratoconjunctivitis, Inflammation, Guillain-Barre Syndrome
Eculizumab biosimilar (Samsung Bioepis)
SB-12
Phase 3 Clinical
Samsung Bioepis
Hemoglobinuria, Paroxysmal
Tesidolumab
NOV-4, LFG-316
Phase 2 Clinical
Novartis Pharma Ag, Morphosys Ag
Hemoglobinuria, Paroxysmal, Wet Macular Degeneration, Geographic Atrophy, Macular Degeneration
Olendalizumab
ALXN-1007
Phase 2 Clinical
Alexion Pharmaceuticals
Graft vs Host Disease, Antiphospholipid Syndrome, Rejection of organ transplantation, Inflammation
Cemdisiran
ALN-CC5
Phase 2 Clinical
Alnylam Pharmaceuticals Inc
Glomerulonephritis, IGA, Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome
ALXN-5500
ALXN-5500
Phase 1 Clinical
Alexion Pharmaceuticals Inc
Hemoglobinuria, Paroxysmal
ALXN-1720
ALXN-1720
Phase 1 Clinical
Alexion Pharmaceuticals
Pexelizumab
Discontinued
Stanford University
Reperfusion Injury, Myocardial Infarction